Condition: Cancer · Sponsor: The University of Texas Medical Branch, Galveston
The aim of this study is characterize the gastrointestinal microbiomes of patient with solid cancer undergoing standard of care treatment with programmed cell death protein 1 (PD-1) /programmed cell death ligand (PD-L1) blockade.
This description comes directly from the study's public registry record.
Kristen McGovern, PhD · 409-772-8126 · kamcgove@utmb.edu
Kate Randolph, BS · 409-223-7891 · kmrandol@utmb.edu
Always discuss trial participation with your own doctor first.
| University of Texas Medical Branch | Galveston, Texas, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06050733